Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced Phase 1/2 data in support of the Phase 3 Aspire study for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, ...

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an ...

Ironsail Pharma is excited to announce the launch of its innovative pharmacy network technology, designed to transform the prescription management process for healthcare providers. This comprehensive ...